(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
First Alert: Light snow through this evening - 2Why won't NASA's Artemis 2 astronauts land on the moon when they get there?
- 3The most effective method to Pick the Right Material Organization: Your Definitive Aide
- 4‘Slender Man’ attacker back in custody. What we know about Morgan Geyser's disappearance and what happens next.
- 5Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- Nitty gritty Manual for Picking Agreeable Tennis shoes
- An Aide On Upgrading Your FICO rating
- How did humans evolve, and will we evolve more?
- Europe’s Airlines Run Low on Fuel
- The Best Games Crossroads in History
- Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space
- Fundamental Home Items Each Animal person Needs
- 6 Methods for further developing Rest Quality
